Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio Study

NCT04340076 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT04340076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04340076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio Study
Lead sponsor
Radboud University Medical Center
Phase
Phase 4
Overall status
Completed
Start date
August 20, 2020
Completion date
January 31, 2025
Enrollment
244 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis, psoriasis vulgaris